Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically

Theralase® Technologies Inc. has announced a significant breakthrough in lung cancer treatment. Their lead drug, Rutherrin®, demonstrated a complete response in a Non-Small Cell Lung Cancer (NSCLC) animal model. The research employed a Lewis Lung Cancer (LLC1) orthotopic model, where mouse lungs implanted with lung cancer cells developed aggressive tumors.

Treated with x-ray radiation, the mice showed tumor regression with the use of x-ray activated Rutherrin®. Tumor progression was reduced four-fold, and survival increased from 26 to 35 days. One mouse even showed a complete response, considered cancer-free after treatment.

Dr. Arkady Mandel highlighted the potential of Rutherrin® in optimizing lung cancer therapy, while CEO Roger DuMoulin-White emphasized its significance for future systemic and targeted cancer therapies. Theralase® now aims to bring this technology to market for various hard-to-treat cancers.